- Home
- MTVA vs OXBR Comparison
MTVA vs OXBR Comparison
Compare MTVA & OXBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTVA
- OXBR
- Stock Information
- Founded
- MTVA 2014
- OXBR 2013
- Country
- MTVA United States
- OXBR Cayman Islands
- Employees
- MTVA N/A
- OXBR N/A
- Industry
- MTVA
- OXBR Property-Casualty Insurers
- Sector
- MTVA
- OXBR Finance
- Exchange
- MTVA NYSE
- OXBR Nasdaq
- Market Cap
- MTVA 14.3M
- OXBR 16.9M
- IPO Year
- MTVA N/A
- OXBR 2014
- Fundamental
- Price
- MTVA $0.71
- OXBR $2.04
- Analyst Decision
- MTVA Strong Buy
- OXBR Strong Buy
- Analyst Count
- MTVA 2
- OXBR 1
- Target Price
- MTVA $7.50
- OXBR $5.00
- AVG Volume (30 Days)
- MTVA 64.8K
- OXBR 198.6K
- Earning Date
- MTVA 08-13-2025
- OXBR 08-07-2025
- Dividend Yield
- MTVA N/A
- OXBR N/A
- EPS Growth
- MTVA N/A
- OXBR N/A
- EPS
- MTVA N/A
- OXBR N/A
- Revenue
- MTVA N/A
- OXBR $1,363,000.00
- Revenue This Year
- MTVA N/A
- OXBR $497.99
- Revenue Next Year
- MTVA N/A
- OXBR $42.14
- P/E Ratio
- MTVA N/A
- OXBR N/A
- Revenue Growth
- MTVA N/A
- OXBR N/A
- 52 Week Low
- MTVA $0.60
- OXBR $1.27
- 52 Week High
- MTVA $4.36
- OXBR $5.81
- Technical
- Relative Strength Index (RSI)
- MTVA N/A
- OXBR 48.09
- Support Level
- MTVA N/A
- OXBR $1.90
- Resistance Level
- MTVA N/A
- OXBR $2.49
- Average True Range (ATR)
- MTVA 0.00
- OXBR 0.27
- MACD
- MTVA 0.00
- OXBR -0.03
- Stochastic Oscillator
- MTVA 0.00
- OXBR 23.61
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
About OXBR Oxbridge Re Holdings Limited
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.